Abstract 3962: Same-species multiplex IF with HCR™Gold IF: Cross-clone benchmarking using Abcam’s oncology-validated primaries

Abstract Background: Spatially resolved, multiplexed immunofluorescence (mIF) is essential for oncology research to profile tumor-immune architecture, track pathway activation, and stratify biomarkers in precious FFPE specimens. Conventional mIF is often limited by species constraints, secondary antibody cross-reactivity, and custom conjugations that slow panel development. Here, we present a plug-and-play workflow that pairs HCR™ Gold IF and Encoder reagents with Abcam’s broad portfolio of primary antibodies to deliver robust same-species multiplexing with minimal optimization and rapid turnaround, streamlining setup from antibody order to imaging in about one work week. Methods: The HCR™ HiFi Encoder binds with high affinity to the Fc domain of unmodified primary antibodies, forming a stable 1:1 complex without compromising antigen recognition. This encoding process is fully compatible with commonly used antibody buffers. Human cancer lines and FFPE tumor sections (e.g., lung, breast, colorectal) were processed using standard fixation/antigen retrieval, permeabilization, and blocking. Off-the-shelf Abcam primary antibodies were HiFi-encoded and detected with fluorophore-labeled HCR™ Gold amplifiers. Multiplexing was achieved by assigning orthogonal HCR™ initiators to each unmodified antibody, allowing simultaneous detection of multiple targets within a single sample. No primary conjugation or iterative stripping steps were required. Panels included oncology-relevant markers for epithelium (panCK), immune subsets (CD3, CD8, CD68), proliferation (Ki67), and stroma (a-SMA). Results: Same-species multiplexing with Abcam primary antibodies produced high-contrast images that preserved expected subcellular/localization patterns across tumor cells, immune compartments, and stroma. Orthogonal Encoders minimized channel crosstalk and HCR™ Gold amplification yielded bright, linear signals suitable for quantitative comparisons across regions of interest. Replicate runs across tissues showed consistent signal-to-background and spatial patterns. Panel build time was markedly reduced; researchers can purchase Abcam antibodies and generate imaging-ready data in ∼5 days, enabling rapid iteration of oncology panels and testing of alternative clones. Conclusions: HCR™ Gold IF with Encoders provides a practical, cancer-focused solution for standardized, same-species multiplex IF using widely available Abcam primary antibodies. The enzyme-free, isothermal amplification preserves epitopes while delivering sensitive, reproducible signals, supporting robust characterization of the tumor microenvironment, pathway activity, and checkpoint expression from limited clinical material. This streamlined, plug-and-play approach lowers barriers to spatial biomarker studies and accelerates discovery and translational research. Citation Format: Wudy Yang, Randy Chen, Harry Choi, Aneesh Acharya, Will Howat. Same-species multiplex IF with HCR™Gold IF: Cross-clone benchmarking using Abcam’s oncology-validated primaries [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3962.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-3962
Primary Topic
Advanced Biosensing Techniques and Applications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 3962: Same-species multiplex IF with HCR™Gold IF: Cross-clone benchmarking using Abcam’s oncology-validated primaries

Will Howat, Harry Choi, R. Chen, Aneesh Acharya et al.
Cancer Research
Advanced Biosensing Techniques and Applications
article

Abstract 3962: Same-species multiplex IF with HCR™Gold IF: Cross-clone benchmarking using Abcam’s oncology-validated primaries

Will Howat, Harry Choi, R. Chen, Aneesh Acharya, Wudy Yang
article en

Abstract

Abstract Background: Spatially resolved, multiplexed immunofluorescence (mIF) is essential for oncology research to profile tumor-immune architecture, track pathway activation, and stratify biomarkers in precious FFPE specimens. Conventional mIF is often limited by species constraints, secondary antibody cross-reactivity, and custom conjugations that slow panel development. Here, we present a plug-and-play workflow that pairs HCR™ Gold IF and Encoder reagents with Abcam’s broad portfolio of primary antibodies to deliver robust same-species multiplexing with minimal optimization and rapid turnaround, streamlining setup from antibody order to imaging in about one work week. Methods: The HCR™ HiFi Encoder binds with high affinity to the Fc domain of unmodified primary antibodies, forming a stable 1:1 complex without compromising antigen recognition. This encoding process is fully compatible with commonly used antibody buffers. Human cancer lines and FFPE tumor sections (e.g., lung, breast, colorectal) were processed using standard fixation/antigen retrieval, permeabilization, and blocking. Off-the-shelf Abcam primary antibodies were HiFi-encoded and detected with fluorophore-labeled HCR™ Gold amplifiers. Multiplexing was achieved by assigning orthogonal HCR™ initiators to each unmodified antibody, allowing simultaneous detection of multiple targets within a single sample. No primary conjugation or iterative stripping steps were required. Panels included oncology-relevant markers for epithelium (panCK), immune subsets (CD3, CD8, CD68), proliferation (Ki67), and stroma (a-SMA). Results: Same-species multiplexing with Abcam primary antibodies produced high-contrast images that preserved expected subcellular/localization patterns across tumor cells, immune compartments, and stroma. Orthogonal Encoders minimized channel crosstalk and HCR™ Gold amplification yielded bright, linear signals suitable for quantitative comparisons across regions of interest. Replicate runs across tissues showed consistent signal-to-background and spatial patterns. Panel build time was markedly reduced; researchers can purchase Abcam antibodies and generate imaging-ready data in ∼5 days, enabling rapid iteration of oncology panels and testing of alternative clones. Conclusions: HCR™ Gold IF with Encoders provides a practical, cancer-focused solution for standardized, same-species multiplex IF using widely available Abcam primary antibodies. The enzyme-free, isothermal amplification preserves epitopes while delivering sensitive, reproducible signals, supporting robust characterization of the tumor microenvironment, pathway activity, and checkpoint expression from limited clinical material. This streamlined, plug-and-play approach lowers barriers to spatial biomarker studies and accelerates discovery and translational research. Citation Format: Wudy Yang, Randy Chen, Harry Choi, Aneesh Acharya, Will Howat. Same-species multiplex IF with HCR™Gold IF: Cross-clone benchmarking using Abcam’s oncology-validated primaries [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3962.

Cancer ResearchVol. 86(7_Supplement)
Intermolecular (United States) (US), Abcam (United Kingdom) (GB)
Openalex Percentile: Top 7%
Advanced Biosensing Techniques and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.